Avita Medical Ltd. (ASX: AVH), the regenerative medicine company, today announced that the United States Food and Drug Administration (FDA) has approved the Company's investigational device exemption (IDE) feasibility study for the use of ReCell® Spray-On-Skin™ in the treatment of hypertrophic dyspigmented scars: i.e., raised and/or discoloured scars.
The approved FDA protocol permits the Company to treat 20 patients with pre-existing scars at up to four U.S. study sites. The treated scars will be assessed for healing and pain on a weekly basis during the initial four weeks post-treatment; at weeks 12 and 24 the treatment site will be assessed for healing and aesthetic outcomes by both the patient and the surgeon.
"We are pleased that the FDA has approved our request to study expanded indications for ReCell," said Dr. William Dolphin, Avita Medical's CEO. "We believe that ReCell offers the potential to deliver significant benefits over currently available options in the treatment of acute and chronic wounds and skin defects. This study will allow us to demonstrate the use of ReCell in the corrective treatment of existing scars with application to the very large cosmetic markets."
The ReCell Scar feasibility study is primarily designed to assess the effectiveness of using ReCell for the treatment of existing scars in a single treatment session, measured as time-to-healing and aesthetic outcomes, compared to the current standard of care which involves dermabrasion of the existing scar and often requires multiple sessions.
Data obtained from this feasibility study will be used to design a larger, statistically powered pivotal clinical investigation. Once the 12-week follow-up with the 20th patient is completed, Avita will submit the feasibility data to the FDA and will seek FDA approval for the pivotal trial protocol.
Avita Medical is currently conducting an FDA-approved study for the use of ReCell in the treatment of acute burn wounds.